Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model

BACKGROUND: Tyrosine kinases are attractive targets for pancreatic cancer therapy because several are over-expressed, including PDGFRα/β, FAK, Src and Lyn. A critical role of mast cells in the development of pancreatic cancer has also been reported. Masitinib is a tyrosine kinase inhibitor that sele...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Humbert, Martine, Castéran, Nathalie, Letard, Sébastien, Hanssens, Katia, Iovanna, Juan, Finetti, Pascal, Bertucci, François, Bader, Thomas, Mansfield, Colin D., Moussy, Alain, Hermine, Olivier, Dubreuil, Patrice
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2010
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2832006/
https://ncbi.nlm.nih.gov/pubmed/20209107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0009430
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars